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ABSTRACT 
Introduction:  HIV associated parotid lymphoepithelial lesions in children are not well 
documented. Most studies have concentrated on the adult population.  
Objectives:  The present study aimed to document the disease, its risk factors and anti-
retroviral treatment outcome in children. 
 
Materials and methods:  The study was conducted at 2 HIV and AIDS facilities weekly over a 
6 month period.  “Parotid swellings” in children below 13 years were analysed.  A 
retrospective medical chart review was conducted. 
Results:  Seventy-one children were included; 47 with swelling (Group 1) and 24 without 
swelling (Group 2).   Thirty-nine had parotid swelling of 1or both glands, 6 had submandibular 
and parotid swelling and 2 with only submandibular swelling.  Twenty-six children in Group 1 
were receiving HAART, 19 reported a reduction in size of lesion, 6 reported no effect and 
only 1 had the lesion after 11 months of HAART. 
Conclusion:  Parotid lymphoid proliferation in children is more common than previously 
reported.  The prevalence of this lesion could not be determined as not all children with 
parotid swelling presenting at the clinics were included in the study.  Children with lower 
viral loads showed an increased risk of developing parotid lymphoid proliferation. The parotid 
lesions responded well to HAART but did not completely resolve.  
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CHAPTER 1 
 
1.0.  INTRODUCTION  
 
HIV infected patients frequently present with oral lesions, which are often the earliest 
indication of HIV infection.  Amongst others, oral lesions can be used in staging of the 
disease, as an indication for initiating therapy and to predict disease progression to AIDS 
(Coogan et al. 2005).   Children may have rapid HIV disease progression due to their 
immature immune system, resulting in the early manifestations of oral lesions (Okunseri et al. 
2003). 
 
HIV associated lesions often involve the parotid glands, presenting as slow growing unilateral 
or bilateral swellings associated with cervical lymphadenopathy (Cleary et al. 1990).  
Numerous terms are used to describe parotid lymphoproliferation, including cystic lymphoid 
hyperplasia (CLHP) (Cleary et al. 1990), benign lymphoepithelial cyst (BLEC) and benign 
lymphoepithelial lesion (BLEL) (Smith et al. 1990) and diffuse infiltrative CD8 lymphocytosis 
syndrome (DILS) (Itescu et al. 1990).  The terminology used is often an indication of the 
whole pathological spectrum of this disease. 
  
The pathogenesis of parotid lymphoid proliferation is still not clear.  In a study by Som et al 
(1995) the lesion was thought to originate from AIDS related proliferation of periparotid and 
intraparotid lymph nodes, resulting in obstruction of the salivary ducts by proliferating 
lymphocytes.  A more popular theory is that the cysts originate from a reactive epithelial 
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proliferation of salivary gland acini and ducts trapped within the parotid lymph nodes 
(Soberman et al. 1991; Mandel et al. 1998).
 
 
HIV related parotid lymphoproliferation is sometimes associated with a slower disease 
progression to AIDS in the adult population (Itescu et al. 1990; Mandel et al. 1998).   
 
 Some 
patients who develop parotid lymphoepithelial lesions are said to have diffuse infiltrative CD8 
lymphocytosis syndrome (Itescu et al. 1990; Mandel et al. 1998).   This syndrome is 
characterised by a CD8 lymphocytic infiltrate associated with the major histocompatabilty 
complex antigen (MHC), HLA-DR5.  The expression of the histocompatabilty antigen HLA-
DR5 is reported to play a role in mediating the immune response to the HIV, resulting in 
slower progression of patients to AIDS (Mandel et al. 1998). 
 
An extensive review of the literature, including a Medline search, hand searches, a search of 
abstracts and conference proceedings was done.  It was evident from the literature that HIV 
associated lymphoproliferative disease of the parotid gland has been very well studied and 
documented in adults (Cleary et al. 1990; Itescu et al. 1990; Mandel et al. 1998), whereas in 
children, this disease has been largely neglected.  Anecdotal reports from HIV clinics indicate 
that the frequency of the lesion in children is increasing and that the clinical manifestations are 
being recognised and regarded by the community as indicative of HIV infection, resulting in 
victimisation of the sufferer.  In addition, reports of malignant transformation in adults are 
increasingly reported in the literature (Chetty, 1996; Del Bono et al. 2000),
 
while not much is 
known of this disease process in children.  The present study documents the disease 
phenomenon in children thereby aiding in defining the entity, expounding its recognition and 
possible treatment strategies. 
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CHAPTER 2 
 
2.0.  AIMS AND OBJECTIVE OF THE STUDY 
 
The aims of this study are to: 
 determine the prevalence of parotid lymphoid proliferation in HIV infected children   
 determine the risk factors for developing parotid lymphoid proliferation 
 determine the treatment outcome of this disease 
The overall objective of the study is to define the clinical characteristics of HIV lymphoid 
proliferation of the parotid glands in children.   
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CHAPTER 3 
 
3.0.  LITERATURE REVIEW 
 
3.1. HIV statistics 
The number of people living with HIV/AIDS has risen globally to 33.4 million in 2007 from 
29 million in 2001 (UNAIDS, 2009).  In 2007, 2.7 million people were newly infected with 
HIV and 2.1 million died from AIDS related illnesses.  The majority (68%) of these infections 
are in Sub-Saharan Africa with an estimate of 22.4 million infected people.  Southern Africa, 
including countries such as Botswana, Lesotho, Mozambique, South Africa, Namibia, 
Zimbabwe and Zambia, is the worst affected region at 32% of total HIV infections.  Women 
make up 61% of people living with HIV in the region.  An estimated 50% to 80% of the HIV 
infected population in Southern Africa are co-infected with tuberculosis (TB) (UNAIDS, 
2009).
 
 
South Africa has the highest number of HIV infections in the world, estimated at 5.7 million in 
2007 from 4.7 million in 2001.  The majority of people infected are women, with a reported 
estimate at 3.2 million.  Children (0-14 years) are estimated to have prevalence of 280 000 
(UNAIDS, 2009).  The majority of the adult HIV infections are through heterosexual contact.  
Paediatric HIV infection is reported through three major routes, namely, maternal 
transmission, transfusion of contaminated blood products and sexual contact, often through 
sexual abuse.  The majority of the children acquire the infection through mother-to-child 
vertical transmission, however, this number has decreased through the introduction of the 
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prevention of mother to child transmission (PMTCT) intervention programme.  In an African 
study by Gisselquist et al (2002) a significant proportion (20%-40%) of HIV infections 
occurred in individuals with HIV negative partners and children born to HIV negative parents.  
HIV transmission was thought to be through improper health care practices often associated 
with lack of infection control and the use of unsafe donor tissues.
 
 
3.2. Oral lesions in HIV and AIDS 
HIV infected individuals often present with opportunistic infections caused by the progressive 
loss of CD4 lymphocytes.  These infections frequently affect the oral cavity.  HIV oral lesions 
have been classified into three groups based on the recommendation by EC Clearinghouse 
(Classification and diagnostic criteria for oral lesions in HIV infection, 1993) namely, those 
that are strongly associated with HIV infection, those less commonly associated with HIV 
infection and those seen in, but not indicative of HIV infection.  Furthermore, oral lesions are 
used in the World Health Organisation (WHO) disease staging system (Proposed ‘World 
Health Organization staging system for HIV infection and disease’, 1993) which predicts 
disease progression to AIDS.  The classification system for paediatric HIV is different from 
that of adults and is based on an age, immune status and clinical category.  A summary of HIV 
and AIDS associated oral lesions documented in the Centre for Disease Control and 
Prevention (CDC) staging 1994
 
is listed in Table 3.1.  
 
An oro-facial manifestation of HIV and AIDS that has shown a marked increase in frequency 
is lymphoid proliferation of the parotid gland (Ortega et al. 2008).  The occurrence of this 
phenomenon in children was reported Sculerati as early as 1990, as non-tender bilateral 
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enlargements of the parotid gland that often persist for months and years.  As mentioned, 
research of HIV parotid gland lymphoid proliferation in the paediatric population is deficient. 
  
Table 3.1. CDC (1994) revised classification system for HIV infection in children less than 13 years: based 
on clinical manifestations
 
Immune category  Clinical oral symptoms  
Category N Not symptomatic  Persistent generalised lymphadenopathy 
Category A    Mildly symptomatic  Lymphadenopathy  
 Parotitis 
Category B   Moderately  
  Symptomatic 
 Oral candidiasis 
 Oral hairy leukoplakia 
 Lymphoid interstitial pneumonia 
 Herpes simples virus stomatitis 
 Herpes zoster 
 Cytomegalovirus infection 
Category C Severely 
Symptomatic 
 Kaposi sarcoma 
 Lymphoma 
 
3.3.       Parotid lymphoid proliferation  
3.3.1.   Terminology  
Since its discovery in the late 1980s (Shugar et al. 1988; Itescu et al. 1989) numerous terms 
have been used to describe lymphoproliferation of the parotid salivary glands in HIV infected 
patients.  These have included HIV benign parotid hypertrophy (Beitler et al. 1999), cystic 
parotid lesions in HIV (Smith, 1990), cystic lymphoepithelial lesions in HIV (Smith, 1990), 
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benign lymphoepithelial cysts of the salivary glands (BLEC) (Smith, 1990), cystic lymphoid 
hyperplasia (CLHP) (Aguirre et al. 2000) and diffuse infiltrative lymphocytosis syndrome 
(DILS) (Itescu et al. 1990). 
 
Dave et al. (2007) have proposed a three tier system to the classification of HIV associated 
lymphocytic parotid gland enlargement in the paediatric population,  
1.  persistent generalised lymphadenopathy (PGL) 
2.  benign lymphoepithelial lesion (BLEL) 
3.  benign lymphoepithelial cyst (BLEC) 
These authors nonetheless emphasise that it is unclear if the lesion is a continuous spectrum of 
disease or distinct entities with different pathogeneses.  In the present study, emphasis is made 
of the fact that until special confirmatory investigations are done in the HIV patient, the 
lesions should be referred to as HIV related parotid lymphoid proliferation of the salivary 
gland, based on the fact that all similar lesions previously investigated demonstrated a 
lymphoid component. 
 
3.3.2.   Clinical presentation  
Lymphoid proliferation of the parotid gland presents as a unilateral and ultimately bilateral 
enlargement often associated with cervical lymphadenopathy (Mandel et a1. 1992; Mandel et 
al. 1998).  Lymphocytic involvement of the submandibular salivary glands has also been 
reported in both paediatric and adult patients (Terry et al. 1991; Chetty, 1996; Rosso et al. 
2006).  The liver, spleen and kidneys may have the lymphocytic infiltrate but the most 
common extraglandular infiltrate occurs in the lungs, often presenting as interstitial 
lymphocytic pneumonitis (LIP) (Som et al. 1995).   
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The lesions can present at any age, the youngest patient reported at 6 months by Soberman et 
al (1991) often with a reported male predominance both in adults and children (Schiødt et al. 
1992; Morales-Aguirre et al. 2005; Rosso et al. 2006).  The prevalence of the parotid lesion in 
the paediatric population is reported at rate of 2-10% (Fonesca
 
et al. 2000; Gaitan-Cepeda et 
al. 2002; Okunseri et al. 2003) however in a South African study by Naidoo and Chikte (2004)
 
a prevalence of 50% was reported.  Children presenting with HIV parotitis with 
lymphadenopathy, hepatomegaly, splenomegaly and upper respiratory infections are 
categorised as mildly asymptomatic according to the CDC (1994) and have a better clinical 
course.  Although bilateral parotid swelling was previously reported in HIV negative 
individuals (Mandel and Surattanont, 2002) the presence of these lesions today is a strong 
indication for HIV testing.   
 
3.3.3.   Pathogenesis 
Due to the differential clinical presentation of the HIV parotid lymphoproliferation (cystic 
versus solid lesion), the pathogenesis of these lesions is still the subject of controversy.  
During embryologic development, 5 to 10 lymph nodes are trapped within the parotid gland.  
The HIV virus is said to induce lymphocytic infiltrate of the intraparotid lymph nodes 
resulting in swelling of the gland (Del Bono et al. 2000).  This is thought to occur during the 
initial stages of HIV infection, thus the term persistent generalised lymphadenopathy (PGL).  
Migration of HIV infected cells from the peripheral blood circulation into the parotid glands is 
postulated to be the initial trigger of lymphoid proliferation and inducing metaplastic changes 
of the ductal epithelium.  A theory supported by the presence of HIV-1 p24 protein within the 
follicular dendritic cells in the germinal centres (Uccini et al. 2000). 
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Lymphocytic infiltrate is mediated by specific major histocompatabilty complex (MHC) class 
alleles (HLA-DR5), which recognise the viral protein expressed by epithelial cells (Mandel et 
al. 1998).  The MHC molecule induces the proliferation of CD8 T lymphocytosis, which is 
thought to suppress viral replication resulting in slower progression of HIV infection to AIDS.  
Expression of HLA-DR5 with proliferation of CD8
 
T cell was also reported in three of the four 
children with parotid enlargement in a study by Soberman et al (1991).
 
 
Cyst formation is seen as a later development in HIV parotid gland disease (Mandel, 1998).  
The cysts are observed to have developed within intraparotid lymph nodes, resulting in 
replacement of nodal tissue.  While cyst formation was originally thought to be due to duct 
obstruction by lymphoid proliferation (Mandel, 1998; Ioachin, 1988) a more favoured 
hypothesis is that they arise from a lymphocytic trigger of glandular epithelium trapped within 
the intraparotid lymph nodes, resulting in cyst formation (Elliot, 1990). 
 
3.3.4. Microscopic Features 
The histology shows parotid tissue with lymphocytic infiltrate organised into follicle and 
germinal centres surrounding islands of epithelial tissue and myoepithelial cells.  Acinar 
atrophy occurs as the lymphoid proliferation often leads to replacement by lymphoid tissue.  
Histological features are similar to that of Sjögren‟s syndrome.  The cystic lesions consist of 
spaces lined by metaplastic squamous or cuboidal epithelium infiltrated by mature 
lymphocytes.  Follicular lymphoid hyperplasia with prominent plasma cells and some 
multinucleated giant cells are often associated with the cyst.  The lumina of the cysts may 
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contain keratinaceous and proteinaceaous debris, which in a study by Uccini et al (2000) was 
found to contain HIV-1 RNA copies. 
 
3.3.5.  Radiographic Features 
A number of imaging techniques are used in the diagnosis of parotid salivary lymphoepithelial 
lesions.  Ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI) are 
effective in the diagnosis of BLEL and BLEC, even in clinically asymptomatic patients.
  
CT 
scans are the primary methods used in the diagnosis of these lesions for evaluation of the size 
and number of cysts within the lesion.  
 
With regard to children, sonography may be preferred over CT scan because it is less invasive 
and does not require sedation.  In a study by Soberman et al (1991)
 
two main sonographic 
patterns were observed.  The first pattern was that of diffuse small and medium hypoechoic or 
anechoic areas with preservation of normal gland architecture whilst the second pattern was 
that of large anechoic areas almost replacing the parotid gland.  Calcification was noted within 
the large anechoic areas of one of the patients.  The study by Martinoli et al (1995) showed 
sonographic patterns ranging from cystic to mixed masses with a predominant solid 
component.  HIV lymphoepithelial lesions are often associated with interstitial pneumonitis.  
Brudnicki et al (2001) showed chest radiographs with pulmonary lymphoid hyperplasia and 
cyst formation. 
 
3.3.6. Treatment 
Treatment options for reactive parotid lymphoproliferative lesions include observation, 
repeated aspiration, antiretroviral medication, sclerosing therapy, radiotherapy and surgery.  
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The traditional treatments of repeated aspiration, sclerosing therapy (Lustig et al. 1998) and 
the least favourable surgical intervention were often used to address the cosmetic concern and 
social stigma associated with the swelling.  
 
3.3.6.1. Radiotherapy 
Radiotherapy was extensively used before the introduction of highly active antiretroviral 
therapy (HAART).  External radiation of 24 gray, i.e. high dose radiation was reported to yield 
better results compared with low dose radiotherapy, with total regression of the lesion (Beitler 
et al. 1991; Kooper et al. 1998).   The use of radiotherapy for a benign lesion is controversial, 
especially considering the possible long term consequence of malignancy associated with 
radiotherapy. 
 
3.3.6.2. Parotidectomy 
Parotidectomy has also been used as an alternative treatment in patients who are stigmatised 
by the presence of the bilateral salivary gland swelling.  Due to the location of the facial nerve 
in the parotid gland, nerve palsy is to be anticipated during parotidectomy.  Surgery, in the 
form of superficial parotidectomy in conjunction with fine needle aspiration (FNA), may be 
used to rule out malignancy (Chetty, 1996; Del Bono et al. 2000).     
 
3.3.6.3. Antiretroviral (ARV) treatment 
The use of ARVs, especially zidovudine, in the management of parotid lymphoid proliferation 
has been documented (Schiødt et al. 1992; Shaha et al. 1993; Hamza et al.2006).
 
 The size of 
the lesions is reported to decrease or disappear as seen in follow-up images of children on 
HAART regimen containing zidovudine (Morales-Aguirre et al. 2005).   At the same time, 
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contradicting reports of an increased frequency of salivary gland disease in patients on 
HAART have been documented (Schmidt-Westhausen et al. 2000; Ortega et al. 2008).
  
The 
lesions may present as a form of immune reconstitution syndrome (IRIS), which is a reaction 
to the rising CD4 count and falling HIV-1 RNA level after the initiation of HAART.  The first 
phase of immune reconstitution occurs in the first three months of therapy and is characterised 
by an increase in circulating naïve and memory CD4 and CD8 cells as well as B lymphocytes.  
The second phase is characterised by an increase in circulating naïve CD4 and CD8 cells and a 
decrease in circulating memory CD8 cells (Powderly et al. 1998).    
  
The pathogenesis of the immune reconstitution syndrome is not fully understood.  It is thought 
to result from a rapid rise in memory CD4 cells which express inflammatory cytokines 
resulting in an exaggerated immune response to previously known pathogens (Ortega et al. 
2008).  IRIS has been described for tuberculosis, cytomegalovirus retinitis, mycobacterium 
avium complexes (MAI), cryptococcus, hepatitis B, hepatitis C and herpes zoster.  The most 
common oral cases reported are an increase in the frequency of human papillomavirus (HPV) 
related oral lesions and salivary gland diseases, especially DILS (Ortega et al. 2008). 
 
3.3.7. Malignant Transformation 
HIV infection predisposes individuals to the risk of cancer (Frisch, 2001).   The most common 
cancers are Kaposi sarcoma and non-Hodgkin lymphoma (NHL).  Risk for cancer is due to 
severe immunosupression associated with the disease.  Malignant transformation of parotid 
benign lymphoepithelial lesion to non-Hodgkin‟s lymphoma (NHL) of B cell type amongst 
HIV infected adult population has been reported (Del Bono et al. 2000).  The use of HAART 
in the management of HIV and AIDS has resulted in most children surviving beyond puberty 
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thereby possibly increasing the risk for malignant transformation of the parotid 
lymphoepithelial lesion.
 
   
 
Due to paucity of research in children with parotid enlargement, very few cases of malignant 
transformation have been reported.  In a study by Rosso et al (2006) only 1 child from a 
sample of 51 children developed NHL during a 6 months follow-up period.  However, the 
primary site of the lymphoma occurrence was the arm and groin area, which according to the 
authors could mean that the occurrence of BLEL and NHL might have been coincidental.  
With the anticipated increasing risk of malignancy, it may be mandatory to do periodic fine 
needle aspiration cytology (FNA) in patients with parotid lymphoepithelial lesions and cysts.  
Unfortunately, FNA is less well tolerated by children making diagnosis challenging for 
countries with a lack of resources. 
  
3.4. Reports of lymphoid proliferation of the parotid glands in children 
As already mentioned, reports of lymphoid proliferation of the parotid gland in children are 
scarce.  Only 6 published reports referring to paediatric HIV parotid lymphoid proliferation 
were found (Table 3.2.).  Since children presenting with the lesion are expected to have a slow 
progression to AIDS, it may be that those who have the lesion are less likely to present for 
medical treatment.  On the other hand, the lesions may have been misdiagnosed by clinicians.  
The South African indication for ARV treatment requires a CD4 count of <350cells/mm
3
 or a 
WHO stage III or  IV, which includes patients with Kaposi‟s sarcoma and lymphoma (The 
South African Antiretroviral Treatment Guidelines, 2010).  Parotid gland swelling is 
categorised as Stage I according to the WHO (1993) and thus patients with parotid gland 
swelling only do not meet the requirements for ARV treatment. 
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Table 3.2.  Published research on HIV paediatric parotid lymphoid proliferation 
Author Date Country Number of 
subjects 
Gender Age distribution 
Goddart et al
 1990 Belgium 4 4F 2-3 years 
Soberman et al
 1991 USA 10  7M/3F 6 months-11 years 
Mayer and Haddad
 1996 USA 1 1F 6 years 
Pinto and Rossi
 2004  Review article   
Morales-Aguirre et al
 2005 Mexico  4  3M/1F 3-12 years 
Rosso et al
 2006 Italy  51  29M/22F 10 months-21 years 
Dave et al
 2007 USA 4  4F 7-17 years 
  
Analysis of these publications (Goddart et al. 1990; Soberman et al. 1991; Mayer and Haddad, 
1996; Pinto and Rossi, 2004; Morales-Aguirre et al. 2005; Rosso et al. 2006; Dave et al. 2007) 
shows that since the appearance of the first report in 1990 (Goddart et al. 1990) only 74 cases 
in children have been documented.  Most of these reports consist of between 1 to 5 cases while 
the largest series from Italy by Rosso et al (2006) consisted of 51 patients.  The gender 
distribution in these published reports included 39 males and 35 females, while the age range 
was between 6 months to 21 years.  Three of the seven documented reports are imaging 
studies and one by Pinto and Rossi (2004),
 
a literature review.   
 
Only 1 child from 73 of the reported cases showed evidence of malignant transformation into 
non Hodgkin‟s lymphoma (NHL) (Rosso et al. 2006).  As stated previously, the primary 
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lymphoma site was not in the parotid glands even though the patient had parotid enlargement.  
Although the presentation of parotitis is an indication for HIV testing, other causes of parotid 
swelling in children should be investigated (Table 3.3.).
 
 
Table 3.3. Causes of bilateral parotid swelling in children (Mandel, 2002)
 
Infective Viral parotitis (mumps) 
Bacterial acute  suppurative parotitis 
Autoimmune Recurrent parotitis  
Congenital Haemangioma 
Lymphangioma 
Dermoid cyst 
 
Neoplastic Pleomorphic adenoma 
MALT lymphoma 
 
The present study thus constitutes one of the largest series documenting HIV parotid gland 
enlargement in children.  In view of the high prevalence of HIV in South Africa, 
characterisation of this entity is important for its recognition and treatment. 
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CHAPTER 4 
 
4.0.  MATERIALS AND METHODS 
 
4.1.  STUDY DESIGN 
This is a cross sectional study of parotid gland swelling among HIV infected children 
compared with children without parotid swelling.    
 
4.2.   STUDY SITE 
The study took place at the HIV and AIDS wellness and treatment centres of the Jubilee and 
Odi District hospitals.  The centres are a joint initiative of the Department of Health and the 
Foundation of Professional Development in partnership with UNAIDS.  Both clinics are 
situated in semi-urban areas, 40km north; outside the Pretoria central business district (CBD).  
The centres offer HIV counselling, testing, wellness and treatment for both adults and 
children. A room with an examination light was allocated at each centre to conduct the 
study.   
 
4.3. SAMPLING METHOD AND STUDY POPULATION 
The study included a review of clinical records as well as examination of paediatric 
patients (O-13 years), who attended the clinics during the period of study (December 2008 
-May 2009) which took place once weekly for 6 months. The estimated average monthly 
attendance of paediatric patients at the Jubilee and Odi District hospitals is 80 and 200 
patients respectively.  Most of the children are required to attend the clinic monthly in 
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order to receive treatment and counselling and as a result most of the children seen over 
the 6 month period were not new to the clinic and not all children with parotid swelling 
agreed to participate in the study. Furthermore, new patients below 13 years were 
constantly seeking treatment at the clinics during the 6 month period of the study but 
outside the allocated time for examination of patients for the study. 
 
4.4.  STUDY SAMPLE   
All paediatric patients who showed any clinical physical modification of the parotid glands 
and a sample of patients with no physical glandular changes were recruited.  All patients in 
this study were confirmed as being infected with HIV by enzyme-linked immunosorbent 
assay (ELISA) and Western Blot assays on first attending the clinic, were informed of their 
HIV status and had received counselling.  The study sample was divided into 2 groups 
based on inclusion and exclusion criteria.   
 
 The inclusion criteria for children in Group 1 included only those children below 13 years 
with parotid swelling/enlargement that had consented to participate in the study.  For the 
children in Group 2, the inclusion criteria included children below 13 years without parotid 
swelling/enlargement and who had consented to participate in the study.  All children over 
13 years of age were excluded from the study.  
 
4.5.   ETHICS  
Ethical clearance for the study (M080926) [Appendix 1] was granted by the Human Research 
Ethics Committee (Medical) of the University of the Witwatersrand to examine the patients 
clinically as well as to view patient hospital files in order to confirm the HIV status of the 
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patient, the CD4 count and the viral load.  Furthermore, permission for the study was granted 
by the Department of Health, Tshwane Metsweding region in order to conduct the study, 
which included the examination of patient records, at the Jubilee and Odi District hospitals 
[Appendix 2].   
 
Parents and guardians of the children to be examined were provided with a participation 
information leaflet and consent forms [Appendices 3(A-C) and 4], which were available in 
English and Setswana.  The staff at the clinics was briefed on the study so that they could 
assist illiterate parents or guardians to fill out the consent form, and to grant permission for 
the clinical examination and access to patient records.  Children, who were able to read 
and write, were also required to give assent.  Patients were allocated numbers for 
identification purposes, to assist with follow-up, to avoid duplication and to guarantee 
anonymity.  Furthermore, informed consent from patients and guardians was obtained for 
the taking and use thereafter of clinical photographs for research and publication purposes.  
 
4.6.   DATA COLLECTION 
Patients were referred for evaluation by the attending staff after routine outpatient 
appointments based on a swelling on the side of the face or in the submandibular area.  A 
clinical examination chart [Appendix 5] was completed on each patient detailing general 
patient demographics, clinical presentation, diagnostic evaluation, mode of HIV 
transmission, the presence and nature of the swelling, glands involved, associated 
symptoms, antiretroviral history and its effect on the lesion.    
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Oral examination of the children was conducted by the principal investigator following 
calibration by a certified calibrator for oral manifestations of HIV disease (certified by 
Guy‟s, Kings and St Thomas Dental Institute and the University of Witwatersrand) following 
repeated inter- and intra- calibration examinations until standardisation was achieved.  The  
examination was based on the recommendation of the WHO Collaborating Centre on Oral 
manifestation of Human Immunodeficiency Virus (Proposed ‘World Health Organization 
staging system for HIV infection and disease’, 1993) using the standard methodology to 
examine extra-oral head and neck, peri-oral and intra-oral soft tissue.  The diagnosis of 
oral and dental lesions was based on clinical presentation and recorded based on the ECC-
Clearinghouse criteria (Classification and diagnostic criteria for oral lesions in HIV 
infection, 1993).     
 
The diagnosis of immune suppression is based on the CDC (1994) revised classification on 
HIV infection in children less than 13 years.
  
All included patients had a confirmed HIV 
status and CD4 counts.  No further investigations, for example ELISA, CD4 counts, viral 
loads, FNA or biopsy, were ordered unless prescribed for medical reasons.  Information 
regarding HIV diagnosis, CD4 counts, viral loads, medical pathology and the type of 
antiretroviral therapy was obtained from the patient files.  
 
The presence of parotid swelling was determined by visual inspection as well as manual 
palpation.  Intra-oral examination was done by the principal investigator using a wooden 
spatula, a mouth mirror and dental probe under artificial and natural lighting.  Patients who 
on examination, were found to require further oral and dental management, were referred 
to the nearest state dental facilities.  
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4.7.       STATISTICAL ANALYSIS  
Statistics used are largely descriptive in nature.  Comparison between the 2 groups was 
carried out using the SAS System.  Significant differences between the experimental and 
control groups were analysed using the Student t test and the Chi square test.  A statistical 
significance level of p = 0.05 was used.  
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CHAPTER 5 
  
5.0.  RESULTS 
 
5.1. Study sample 
A total of 71 HIV infected paediatric patients, 38 males and 33 females participated in 
this study (Table 5.1).  There were 47 children with parotid swelling (Group 1) and 24 
without the swelling (Group 2). 
 
5.2. Frequency  
As mentioned in Chapter 4 (4.1.) many of the children seen over the 6 month period 
of the study were not new patients but were there to receive treatment and 
counselling.  Even though new HIV infected paediatric patients were continually 
attending the clinic, only those patients with parotid swelling attending the clinic 
during the time of the investigation were included.  It was therefore not possible to 
determine the frequency or incidence of parotid swelling in this population.  
Anecdotal estimations by the clinic staff indicate that approximately 1 in 5 of the 
children attending the clinic for the first time showed parotid swellings. 
 
5.3. Gender 
The patients in Group 1 comprised 26 (55%) males and 21 (45%) females and those in 
Group 2 consisted of 12 (50%) males and 12 (50%) females (Table 5.1), [Chi square 
test; p = 0.80]. 
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Table 5.1. Epidemiologic and clinical characteristics of HIV infected paediatric patients 
 
 
Group 1 
Children with parotid enlargement 
Group 2 
Children without parotid enlargement 
Total 47 24 
Gender  
o Male 
o Female 
 
26 
21 
 
12 
12 
Age (years)  
o Range 
o Mean 
 
2-12.8 
7.00 
 
1-12.7 
6.28 
Immunological stage  
(CDC category) 
1 
2 
3 
 
 
  9 (19.47%) 
14 (30.43%) 
23 (50.0%) 
 
 
  3 (12.50%) 
  9 (37.50%) 
12 (50.0%) 
CD4 cell count range (%)  
at diagnosis 
at present 
 
19 (1.24%)-2325 (30.91%) 
83 (9.46%)-1830 (43.80%) 
 
12 (0.87%)-1198 (22.10%) 
16 (13.50%)-1646 (23.80%) 
Viral load  range  
at diagnosis 
at present 
 
2100-340 000 
Lower than detactable-920 
 
2500-2 400 000 
Lower than detactable-6100 
Children on HAART 26 (53.32%) 19 (79.17%) 
Not on treatment 21 (44.68%)   5 (20.43%) 
ARV regimen 26 (d4T, 3TC, EFV) 18 (d4T, 3TC, EFV) 
  1 (d4T, 3TC, Kaletra) 
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5.4. Age distribution 
The age of the children in Group 1 ranged from 2 to12.8 years and those in Group 2 
ranged from 1 to12.7 years (Table 5.2; Figure 5.1).  The difference in ages between the 
2 groups was not significant (p = 0.35).  
 
Table 5.2. Statistical comparison of age difference between children in Group 1 and Group 2 
P = 0.35 N Mean SD SEM 
Group 1 47 7.00 3.05 0.44 
Group 2 24 6.28 3.43 0.70 
 
 
 
Figure 5.1. Age distribution of children in Group 1 (blue) compared to those in Group 2 (red)  
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5.5. HIV transmission 
The route of HIV infection was predominantly vertical.  Majority of the children had 
HIV infected mothers or one or both parents who had died from HIV related illnesses, 
with the exception of 4 children whose mothers were not tested.   
 
5.6. CD 4 cell count 
First visit (day of HIV diagnosis) and current value CD4 cell counts were available. 
The median CD4 cell count at diagnosis for Group 1 was 382.02 (14.85%) with first 
values ranging from 19 cells/mm
3 
(1.24%) to 2325 cells/mm
3 
(30.90%) and current 
median values at 552.95 cells/ mm
3 
with ranges from
 
83 cells/mm
3 
(9.46%) to 1830 
cells/mm
3
 (43.80%).  Group 2 median CD4 count was 433.54 cells/mm
3 
(11.31%), 
ranging from 12 cells/mm
3 
(0.87%) to 1198 cells/mm
3
 (22.10%) for first values and 
median of 680 cells/mm
3 
with ranges of 16 cells/mm
3 
(13.50%) to 1646 cells/mm
3 
(23.80%) for current values.  The CD4 cell count at diagnosis was not available for 
only 1 of the 72 children.  This difference was not statistically significant (Tables 5.1. 
and 5.3.). 
 
Table 5.3. Statistical comparison of CD4 cell count between children in Groups 1 and 2 at diagnosis 
(A) and during study period (B) 
P = 0.34 N Mean SD 
Group 1 A 46 379.68 381.65 
               B 22 536.13 389.33 
Group 2 A 24 433.58 336.29 
                B 13 663.79 467.79 
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5.7. Viral loads 
For children in Group 1, the viral loads at diagnosis ranged from 83 to 340 000 while 
the current values ranged from lower than detectable values to 920.  Group 2 children 
had diagnosis values ranging from 2500 to 2400 000 and current values ranging from 
lower than detectable to 6100 (Tables 5.1. and 5.4.).  The difference in values at 
diagnosis was significant (p = 0.02).  With regard to children in Group 1, the viral 
loads appeared to be higher in the females as compared to the males, however this 
difference was not statistically significant (p = 0.17) (Table 5.5.). 
 
Table 5.4. Statistical comparison of viral loads in children in Group 1 and Group 2 
P = 0.02 N Mean SD 
Group 1 31 71394.29 113184.08 
Group 2 18 361805.56 708648.61 
 
Table 5.5. Statistical comparison of viral loads in children in Group 1 
P = 0.17    N Mean SD 
Male    18 60 484.61 15 871.44 
Female    13 368 884.62 255 630.08 
 
5.8. CDC classification 
Most of the children in Group 1 belonged in CDC immunological category 3 [23 
(50.0%)], 14 (30.43%) in category 2 and 9 (19.57%) in category 1. CD4+ lymphocyte 
data was not available for 1 child.  The majority of the children in Group 2 were in the 
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immune category 3 [12 (50%)], 9 (37.50%) in category 2 and 3 (12.50%) in category 1 
(Table 5.1.). 
 
5.9. ARV treatment 
26 (55.32%) of Group 1 children and 19 (79.17%) of Group 2 children were receiving 
HAART consisting of stavudine (d4T), lamivudine (3TC) and efavirenz (EFV).  Only 
1 child in Group 2 was on regimen 2 (second line therapy) consisting of stavudine 
(d4T), lamivudine (3TC) and lopinavir / ritinovir (Kaletra).  21 (44.68%) of the 
children in Group 1 and 5 (20.83%) of those in Group 2 were not on ARV treatment.   
 
Of the children with parotid enlargement (Group 1), 20 (73.08%) showed a reduction 
in the size of the parotid enlargement after the initiation of HAART, however the 
swelling did not completely resolve.  The mean duration of HAART amongst this 
group was 9.89 months.  HAART had no effect on 6 children (23.08%) and only 1 
child (3.84%) reported that parotid swelling appeared after starting HAART.  The 
mean duration of HAART for children with no effect on parotid enlargement was 12 
months. 
 
5.10. Clinical presentation of facial swellings 
Of the children in Group 1 with facial swellings, 39 (82.98%) had swelling of 1 or both 
parotid glands (Figures 5.2.A-D and 5.3.A-C), while 6 (12.77%) had both parotid and 
submandibular gland involvement.  Submandibular gland enlargement only was 
present in 2 (4.25%) patients (Table 5.5.).  The parotid swelling had a hard texture in 
36 patients (76.59%) and presented as a soft swelling in 11 children (23.40%).  Both 
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the children and the accompanying adults indicated that the swelling started initially 
unilaterally before becoming bilateral, usually within 6 months.  The size of the parotid 
swelling ranged from about 2 -3mm (Figure 5.2.B) to over 5cm in diameter in which 
cases the ear lobes were elevated (Figure 5.2.A,C,D).  All the children in both groups 
(100%) had cervical lymphadenopathy (Figure 5.3.).  
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Figure 5.2. Children in Group 1 showing bilateral parotid swelling (A and D), with enlargement of the left 
parotid gland being more marked than the swelling on the right side; unilateral swelling of the right 
parotid gland (C and D).  
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Figure 5.3. Posterior view of the unilateral (A and B) and bilateral parotid enlargement with cervical 
lymphadenopathy in children in Group 1 (C) 
 
A 
B 
C 
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Table 5.6. Parotid lesions and associated oro-facial manifestations and treatment outcome 
 Group 1 Group 2 
Total  47 24 
Parotid enlargement only 39 (82.98%) 0 
Parotid and submandibular   6 (12.77%) 0 
Submandibular enlargement only   2 (4.25%) 0 
 
Texture 
Hard 
Soft 
 
36 (76.59%) 
11 (23.40%) 
 
0 
0 
 
Associated symptoms 
Parotid pain  
Dry mouth 
Dental  caries 
Oral candidiasis 
Mouth ulcers 
Gingivitis 
 
12 (25.53%) 
  2 (4.25%) 
28 (59.57%) 
20 (42.55%) 
  5 (10.63%) 
  5 (10.63%) 
 
0 
0 
12 (50%) 
  9 (37.5%) 
  3 (12.5%) 
  3 (12.5%) 
Total on HAART 26 (55.32%) 19 (79.17%) 
Effects of HAART on lesion 
No effect 
Subsided 
Had lesion after HAART 
 
  5 (19.23%) 
20 (76.92%) 
  1 (3.85%) 
 
 
Cervical lymphadenopathy 47 (100%)   5 (20.83%) 
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5.11. Other oral lesions 
The children in Group 1 had a higher prevalence of oral lesions as compared to the 
children in Group 2 (Table 5.6.; Figure 5.4.).  The prevalence of dental caries (59.57%) 
and oral candidiasis (42.55%) (Figure 5.5.) was higher in Group 1 as compared with 
those in Group 2, which showed a prevalence for dental caries (50.0%) and oral 
candidiasis (37.0%).  For children in Group 1 (Figure 5.5.) dental caries was the most 
prevalent oral disease, present in 28 (59.57%) children followed by oral candidiasis in 
20 (42.44%) patients (Figures 5.6. and 5.7.) and pain overlying the parotid area, 
reported in 12 (25.53%) children.  Only 5 (10.63%) children in this group presented 
with oral ulcers and gingivitis.  One child in Group 2 presented with focal epithelial 
hyperplasia (Heck‟s disease) (Figure 5.8.).  
 
Table 5.7. Oral lesions in HIV positive children with (Group 1) and without (Group 2) parotid swelling/ 
enlargement  
 
Group 1 (47) Group 2 (24) 
Oral candidiasis 20 (42.55%)   9 (37.5%) 
Caries 28 (59.57%) 12 (50%) 
Gingivitis   5 (10.63%)   3 (12.5%) 
Mouth ulcers   5 (10.63%)   3 (12.5%) 
Viral warts   0   1 (4.17%) 
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Figure 5.4. Distribution of associated oral lesions of children in Group 1 
 
 
 
Figure 5.5. A comparison of oral lesions in children with and without parotid lymphoid proliferation 
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Figure 5.6. Erythematous candidiasis of the tongue with extension to the tonsillar fauces and soft palate  
 
 
 
 
 
 
 
 
 
Figure 5.7. Bilateral angular chelitis (oral candidiasis) and dental caries of the mandibular central incisors 
 
 
 
 
 
 
 
 
 
Figure 5.8. Focal epithelial hyperplasia (Heck’s disease) of the lower labial mucosa and gingiva
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5.12  Concomitant systemic pathology 
The concomitant medical conditions suffered by these children included TB and varicella-
zoster.  The frequency of these and other conditions are listed in Table 5.4.  It can be seen that 
more patients in Group 2 suffered from TB whilst the frequency of the other lesions did not 
seem to be significantly different (Figure 5.9.). 
 
 
 
Table 5.8. Concomitant medical pathology in HIV positive children with (Group 1) and without (Group 2) 
parotid lymphoid proliferation 
 Group 1 (47) Group 2 (24) 
Tuberculosis   16 (34%) 13 (54.17%) 
Varicella-zoster   5 (10.63%)   3 (12.5%) 
Otitis media   2 (4.25%)   0 
Hepato/splenomegaly   4 (8.51%)   0 
Skin rash   3 (6.38%)   1 (4.17%) 
Cough/respiratory infection   2 (4.25%)   1 (4.17%) 
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Figure 5.9. Medical pathology in HIV positive children with (Group 1) and without (Group 2) parotid 
lymphoid proliferation 
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CHAPTER 6 
 
6.0. Discussion 
 
Parotid lymphoid proliferation in children is not as well documented as in the adult population 
with relatively few cases having been reported (Table 3.2.).  This study is the largest series in 
which the factors for the development of lymphoid proliferation in the parotid gland in 
children are documented.  As previously mentioned, the prevalence of this condition in the 
sample we studied was unknown, but we estimated involvement of up to 20% or 1 in 5 of the 
children attending the clinics to show evidence of parotid swelling.  The frequency in adults is 
estimated at 2-10% (Mandel et al. 1992; Mandel et al. 1998; Terry et al. 1991; Schiødt
 
et al. 
1992; Kreisel et al. 2010) while a frequency of 50% was reported by Chikte and Naidoo 
(2004)
 
in institutionalised children in South Africa.  
 
The previous largest series was a report by Rosso et al (2006) consisting of 51 patients in 
which ultrasonography (USG) was used to correlate the USG pattern and clinical and 
immunological condition of the patients.  Their study is similar to the present study in that it 
was also conducted in vertically infected HIV patients with parotid gland and neck lymph 
node enlargement and included CDC staging, CD4 counts, viral loads and patients on 
HAART.  However, whereas the present study included children ranging from 2 to 12 years 
with a male predominance of (1.2:1), the series reported by Rosso et al (2006),
 
included 
children from 10 to 256 months (21.3 years), and thus their study was not restricted entirely to 
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children.  Similarly, the series reported by Dave et al (2007) included a 17 year old patient.  It 
is interesting to observe that no children younger than 2 years were found in this study.  This is 
in contrast to other reported paediatric studies (Table 3.1.) where infants as young as 6 months 
were included in their series.  Since the mode of HIV transmission is vertical in the children, it 
can only be speculated that the parotid lesion appears once the CD4 count has dropped 
significantly or the immune system has matured somewhat.  This provides opportunity for 
future research.   
 
Published reports of HIV related parotid lymphoid proliferation in adults showed a distinct 
male predominance with reports by Soberman et al (1991) [2.3:1], Schiødt et al (1992) [21:1], 
Morales-Aguirre et al (2005) [3:1], Rosso et al (2006) [1.3:1] and Martinoli et al (1995) 
[3.5:1] all showing a similar distinct male predominance.  The gender distribution in this study 
was almost equal (1.2:1).  This is not surprising since the mode of HIV transmission differs 
between adults and children.  Children generally acquire HIV through parental vertical 
transmission while most adults in Africa are infected by sexual transmission. 
 
All of the children included in the present study were black, however in other studies from 
around the world the parotid lymphoproliferation has been reported in blacks, Hispanics and 
whites.  The association of HIV lymphoid proliferation of the parotid glands and MHC class II 
allele DR5 amongst black (African) patients has been reported (Itescu et al. 1990).   According 
to these authors, the presence of HLA-DR5 confers a protection against HIV infection.  As in 
the adult population, the expression of HLA DR5 in children with CD8 lymphocytosis has 
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been documented (Soberman et al. 1991).  Currently there are 4 known subtypes of HLA-DR5 
(Itescu et al. 1989), and in particular the allelic subtype JMV has been isolated in black 
patients with DILS (Itescu et al. 1990).  According to these authors, the JMV subtype is rare in 
Caucasians.  Other mechanisms to explain the pathogenesis of the parotid lymphoid 
hyperplasia should therefore be considered because all the children in this study, including 
those without the parotid enlargement were black Africans.  Furthermore, there may be other 
HLA-DR5 subtypes in black Africans which may explain why some black patients present 
with parotid lymphoid hyperplasia and others do not. 
 
When the data of the viral load on presentation in the study group (Group1) was compared 
with similar data from the control group (Group 2), the difference was significant; with the 
children in the study group showing lower viral load values, often below 100 000 RNA 
copies/ml.  Analysis of the data of the viral loads related to possible gender differences within 
each group failed to show any significant differences.  Our results seem to indicate that low 
viral load is related to a higher risk of developing parotid lymphoid hyperplasia.  The possible 
nature of this relationship is not understood but seems to be consistent with the observation 
that children with parotid lesions have a better prognosis than those without the lesion.  It is 
not the parotid lesion which confers the better prognosis but the low viral loads, with the 
parotid lesions merely being an indicator of such viral load.  It should be noted that 
comparison of the values before and after treatment within the same group and in between the 
2 groups was not done as there was no standardisation in the period of treatment the children 
had undergone. 
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Morales-Aguirre et al (2005) reported viral loads of below 100 000 copies/ml (8591, 58 671 
and 8817), with only one male child having a viral load of 138 886 copies/ml.  Similarly, Dave 
et al (2007) also reported viral loads below 100 000 copies/ml, however both these authors 
(Morales-Aguirre et al. 2005; Dave et al. 2007) 
 
did not document any correlation between low 
viral load and the risk of developing parotid lymphoid hyperplasia.  In our study and like 
previous reports (Morales-Aguirre et al. 2005; Dave et al. 2007) HIV infection was acquired 
by vertical transmission.  Since the majority of the children acquired HIV through vertical 
transmission, it is possible that the maternal viral load may have influenced the difference in 
viral load in the children and hence the development of the parotid lesion (Ioannidis et al. 
2004).  Children with low viral load could have mounted an effective immune response 
resulting in an enhanced proliferation of lymphoid tissue in both nodal and extranodal sites. 
 
The presence of parotid gland lymphoepithelial lesions is often associated with a slower HIV 
disease progression in both adults and children (Katz et al.1992; Rosso et al. 2006).  No 
correlation was found between the presence of these lesions with the CDC classification, as 
the parotid  lesions were noted in immune categories A to C (Table 5.1.).  In this study, the 
majority of the children in Group 1 (50.0%) were in immune category 3 as were majority of 
children in Group 2, (50.0%).  This demonstrates that the lesion can be present at any stage of 
the HIV infection, including severely immune compromised children.  Schiødt et al. (1992)
 
showed 5 HIV infected adult patients (22.73%) with AIDS at the time when parotid swelling 
was diagnosed.  In a study by Rosso et al (2006), only 2 patients with parotid lymphoepithelial 
lesions were asymptomatic.  These findings, however, are in contrast to those reported by 
Morales-Aguirre et al (2005), where none of the children with parotid lymphoproliferation was 
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in category C.  However, their series consisted of only 4 cases as compared with 47 children 
with lesions in this study and 22 in the study by Schiødt et al (1992). 
 
Lymphoid proliferation usually presents as a painless, slow growing often bilateral swelling 
often associated with cervical lymphadenopathy. The parotid glands are commonly affected 
(Itescu et al. 1989; Sculerati et al. 1990; Mayer and Haddad, 1990; Dave et al. 2007)
 
however 
involvement of other salivary glands has also been reported (Smith, 1990; Elliot and Oertel, 
1990; Chetty, 1996; Terry et al. 1991).  Only two (4.25%) children with submandibular 
swelling were seen in the present study.  All children (100%) in Group 1 had cervical 
lymphadenopathy, while only 5 of the children in Group 2 (20.83%) had cervical 
lymphadenopathy.  This shows that some children may present only with cervical 
lymphadenopathy, without the presence of salivary gland swelling.  Most patients claimed to 
have experienced phases of parotid and submandibular swelling lasting from 2 to 6 weeks with 
alternating bouts of spontaneous remission and recurrences occurring within weeks or months.  
This however could not be assessed or confirmed via clinical examination of the patients in the 
clinics.  As documented in the clinical history, the texture also correlated with the phases of 
the swellings, with the firmer, more solid lesions associated with the active phases of the 
disease, and the softer, more fluctuant and perhaps cystic lesions occurring during the 
remission phases.  Lesions often involved one gland initially and progressed to bilateral 
involvement, as reported previously (Elliot and Oertel, 1990; Morales-Aguirre et al. 2005; 
Dave at al. 2007).    
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The presence of oral candidiasis and parotid enlargement are said to have prognostic 
significance in disease progression to AIDS (Katz et al. 1993; Magalhaes et al. 2001). 
According to these authors, oral candidiasis is associated with a poor prognosis whereas the 
presence of parotid enlargement is associated with a better prognosis.  A report by Gaitan-
Cepada et al (2002) found no correlation between HIV associated oral lesions in children and 
the CD4 count and viral load.   
 
The most common oral infection in HIV infected children is oral candidiasis (Magalhaes et al. 
2001; Gaitan-Cepada et al. 2002).  Only 6 of the 47 children (12.77%) in the present study 
were free of associated oral symptoms.  The majority of the children presented with dental 
caries (59.57%), oral candidiasis (42.55%) and pain overlying the parotid area (25.45%).  
Pinto et al (2004)
 
reported a
 
link between the presence of xerostomia and the occurrence of 
Candida, only 2 children (4.25%) in the study complained of a dry mouth.  They further 
suggest that oral candidiasis in children is mainly due to an immature immune system or 
immune suppression.  Schiødt et al (1992) reported that salivary flow rates were more likely to 
be related to the degree of inflammatory infiltrate in the gland, rather than the degree of 
immunosuppression.  The presence of dental caries in children may be due to poor oral 
hygiene and/or to the prolonged use of sugar containing medication as noted in the clinical 
history (Pomarico et al. 2008).  
 
Reports of parotid lymphoid involvement in children often show features that are similar to 
those reported in the adult population (Itescu et al. 1990; Schiødt et al. 1992).  However, based 
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on the literature review, it appears that the association between parotid lymphoproliferation 
and lymphoid interstitial pneumonitis (LIP) is primarily reported in the paediatric HIV 
population (Sculerati and Borkowsky, 1990; Soberman et al. 1991; Lepage et al. 1991; Mayer 
and Haddad, 1996).  None of the children in this study had LIP; however 16 (34.04%) children 
in Group 1 presented with pulmonary TB and 13 (54.17%) children in Group 2.  In South 
Africa, 50% to 80% of HIV infected individuals are co-infected with TB (HIV and AIDS and 
STI strategic plan for South Africa 2007-2011, 2009). 
 
Lymphocytic infiltrates of other organs especially the liver have been reported in the literature 
(Itescu et al. 1990; Mayer and Haddad, 1996).  The presence of hepatosplenomegaly was 
noted in 4 (8.51%) children in Group 1.  None of the children in Group 2 presented with 
hepatomegaly or splenomegaly.  Patients presenting with parotid swelling, cervical 
lymphadenopathy and hepato-splenomegaly often present with DILS (Itescu et al. 1990; 
Mandel et al. 1998).  Without histological confirmation, it is uncertain whether the 4 patients 
in our study had DILS; however they did present with 3 clinical symptoms and signs: namely 
parotid gland enlargement, cervical lymphadenopathy and hepato-splenomegaly, which are 
consistent with DILS.  The 4 children comprised 3 males and 1 female with an initial viral 
load ranging from 12 000 to 31 000.  All the male children were not on ARV treatment.  The 
lower viral loads observed in these children may be an indication of the role of the 
lymphocytosis in viral suppression.    
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The use of antiretroviral drugs especially AZT (zidovudine) has been shown to reduce and 
even eliminate the parotid lymphoproliferative enlargement (Terry et al. 1991; Uccini et al. 
2000).  In the present study the parotid enlargement subsided but did not completely resolve in 
20 (76.92%) children and showed no effect in 5 children (19.23%).  Children whose lesions 
persisted had been on HAART for 3 to 36 months.  One (3.85%) child developed parotid 
enlargement following the initiation of HAART.  None of the children in this study were on 
AZT.  The parotid lymphoproliferative enlargement may be part of an immune reconstitution 
inflammatory syndrome (IRIS) (Powderly et al. 1998) as the parotid lesion appeared 8 months 
after ARV treatment.  Studies conducted have mainly concentrated on oral lesions after the 
initiation of HAART (Aquino-Garcia et al. 2008; Hamza et al. 2006) and no studies have 
focused on the development of parotid lymphoepithelial lesions following the institution of 
ARV treatment as part of the oro-facial manifestations of HIV and AIDS. 
 
Although fewer studies of the parotid lymphoepithelial lesions have been documented in 
children than adults, it is important to recognise parotid swelling in children as it is important 
in the diagnosis of HIV in this population.  Unlike reports in the adult population (Shugar et al. 
1988; Itescu et al. 1989; Cleary and Batsakis, 1990; Itescu et al. 1990; Mandel et al. 1998)  
 
parotid lymphoproliferation in children may be present at any CD4 count and CDC 
classification (Rosso et al. 2006; Dave et al. 2007).  Also, the parotid lesion in children goes 
through phases of proliferation and remission, in contrast with the adult population where slow 
growing parotid lesions of up to 7 years have been reported (Mandel et al. 1998).   
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The role HIV viral load plays in the development of the parotid lymphoepithelial lesions has 
never been explored, with most studies reporting on CD4 and CD8 counts and correlating 
these to the development (Itescu et al. 1990; Mandel et al. 1998),  radiological presentation 
(Shugar et al. 1988; Soberman et al. 1991; Som et al. 1995; Morales-Aguirre et al. 2005; 
Rosso et al. 2006; Dave et al. 2007) and histological classification (Smith, 1990; Mayer and 
Haddad, 1996; Uccini et al. 2000; Dave et al. 2007) of these lesions.  Cytology and imaging 
studies are not carried out routinely, however, the recording of CD4 count and HIV RNA viral 
loads are standard in HIV clinics in South Africa.  Records of CD4 cell count and viral loads 
may be used to predict patient progression from HIV infection to AIDS, especially in resource 
poor settings. 
 
A weakness of this study is the lack of cytology or imaging correlation, and more importantly 
the lack of histological confirmation of the parotid lymphoepithelial lesions.  As stated 
previously in the literature review, other causes of parotid swelling in children need to be 
considered.  Even though the lymphoid proliferations were not confirmed cytologically or 
histologically, given the strong association between parotid gland swelling and HIV infection, 
based on evidence of clinically similar lesions in HIV positive children described in the 
literature, these swellings are probably due to HIV induced lymphoepithelial proliferation.  
Vertically HIV infected children are surviving beyond 15 years of age mainly due to the use of 
ARVs and are therefore at a prolonged risk for cancer development (Frisch et al. 2001).  A 
longitudinal follow-up study will be useful. 
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CHAPTER 7 
 
7.0. CONCLUSION 
This study has documented the largest global series of parotid lymphoproliferation in 
vertically infected HIV children.  It was not possible to determine the prevalence of the disease 
in the population studied.  There was no difference in demographic data, nor was there any 
correlation with regard to CD4 cell count and CDC classification in children presenting with 
HIV lymphoid proliferation of the parotid glands and children who do not have the parotid 
lymphoid proliferation.  There was however a correlation between viral load and the risk of 
developing parotid lymphoid proliferation with children with lower viral loads being at an 
increased risk.   
 
Although the exact nature of the relationship between parotid lymphoid proliferation and viral 
load is not fully understood, it might explain why children with parotid lymphoid proliferation 
seem to have a better prognosis to HIV infection than children without parotid lesions; i.e. it is 
not the parotid lesions which confer a better prognosis but the lower viral load, with the 
parotid lesions merely being a visible manifestation of the lower viral loads. The parotid 
swellings responded well to ARV treatment, however, they did not completely resolve.  Only 
one child developed parotid enlargement after ARV initiation. 
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Appendix 3A: Participation information form (English) 
 
Study number: M080926 
Study title:  Lymphoid Proliferation of the parotid gland in paediatric patients with HIV infection. 
Investigator:  Dr Tsholofelo Kungoane 
Institution: University of the Witwatersrand, Johannesburg 
Contact number: 0827289269/ 0127032732 
Ethics chairman contact details: 011 7171234 
Dear parent/ guardian. 
Hello.  My name is Tsholofelo Kungoane.  I am a student doing a master‟s degree at the 
University of the Witwatersrand, WITS.  I am currently undertaking a study as part of my 
degree and request your help by allowing your child to participate.   
In this study, I want to examine occurrence of swelling on the side of the face in children who 
are infected with the HIV, in order to identify the effects of the swelling in predicting the 
improvement of the disease.  The intention is create awareness of parotid swellings and to 
encourage early diagnosis and treatment.    
The examination will be carried out during the routine check-up of your child.  It involves 
physical palpation for facial and neck swellings.  I will also check your child‟s mouth for 
rotten teeth, dryness, swollen gums and oral infection.  I also need your permission to access 
your child‟s medical record for information regarding CD4 counts and viral loads and to use 
the information collected in the study.  I will also take photos which will be used for the study. 
After examination, should we find that your child needs any further dental treatment, he/she 
will be referred to the nearest state dental facility for treatment.  If you wish, you may take 
him/her to a private dentist at own cost.  Please note that this is an anonymous study, and you 
and your child‟s name will remain anonymous.  
The examination is voluntary with no financial compensation.  If you do not want your child 
to participate in the study you may opt do so; you may also withdraw your child from the 
study at any point.  This will not be held against you or your child. 
Please read the document carefully before agreeing to participate.  If you do not understand 
the contents, do not hesitate to call me on the above numbers. 
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Appendix 3B: Participation form for children  
 
Study number: M080926 
Study title:  Lymphoid Proliferation of the parotid gland in paediatric patients with HIV infection. 
Investigator:  Dr Tsholofelo Kungoane 
Institution: University of the Witwatersrand, Johannesburg 
Contact number: 0827289269/ 0127032732 
Ethics chairman contact details: 011 717 1234 
 
Hello. 
My name is Tsholofelo; I am a dentist and a student from WITS. I am doing a study/ 
assignment for my studies at WITS and I need your help in completing the study. 
You are invited to take part by giving me permission to examine you for any swelling of the 
face and neck. The examination is painless procedure using only gloved hands. I also ask for 
permission to look at your file and take photos. The information found will be used for the 
study. If after the examination you have rotten teeth, I will, with your permission refer you to a 
local dental clinic. 
This is a nameless study. No other person except for me will know who you are. You are free 
to refuse the examination. Nobody can force you to participate, even the nursing sister, your 
parent or guardian  
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Appendix 3C: Participation information form (Setswana) 
 
Study number: M080926 
Study title:  Lymphoid Proliferation of the parotid gland in paediatric patients with HIV infection. 
Investigator:  Dr Tsholofelo Kungoane 
Institution: University of the Witwatersrand, Johannesburg 
Contact number: 0827289269/ 0127032732 
Ethics chairman contact details: 0117171234 
 
Go motswadi le motlhokomedi wa ngwana 
Madume. Ke nna Tsholofelo Kungoane, moithuti wa masters ko WITS. Ke kopa tetla ya gago 
go tlhatlhoba le go lebelela faele ya ngwana ya sepetlela. Mo tlhatlhobong e, ke tlile go 
lebelela bolwetsi ba maue bo bo tlhaselang bana ba ba na leng kokwana-tlhoko ya HIV. 
Tlhatlhobo e, e tlile go dirwa ka letsatsi la ngwana la go tla bookelong. Ke tlile go tlhatlhoba 
le legano la ngwana go lebelela meno a go bola, marinini a go ruruga le malwetse a mangwe a 
legano. Ke kopa o ntetlelle go okomela faele ya ngwana mo ke tlo go lebelela dilo ditshwana 
le di CD4 le viral load le tetla ya go tsaya ditshwantsho. Fa go ka fitlhelwa gore ngwana o 
tlhoka tlhokomelo ya legano, o tlile go romelwa ko bookelong kana tliliniking ya meno. 
O itsisewe gore tlhatlhobo e ke mahala, ka boithapo (voluntary). Fa o sa dumele tlhatlhobo e, o 
kana wa dira jalo ntle le kotlhao. Fa o na le dipotso, ntetsetse mogala mo dinomorong tse di 
filweng. 
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Appendix 4: Consent form 
 
Study number: M080926 
Study title:  Lymphoid Proliferation of the parotid gland in paediatric patients with HIV infection. 
Investigator:  Dr Tsholofelo Kungoane 
Institution: University of the Witwatersrand, Johannesburg 
Contact number: 0827289269/ 0127032732 
Ethics chairman contact details: 011 7171234 
 
Please complete and return. 
 
I, the undersign parent/guardian of ...................................................agree to have my child 
participate in the study.  I have read and understand the purpose of the study and the 
procedures involved.  I also understand that I am free to withdraw my child from the study at 
any time without any consequences to me or my child. I also give permission for photos to be 
taken and their use for the purpose of the study. 
 
...................................................................................................................... .............................. 
Parent/Guardian Name                            Signature/thumbprint                                          Date  
 
 
 My name is                                          .My parent/guardian has explained to me about the 
study.  I understand what will be done in my mouth and face. I am aware that even if my 
parent/ guardian agree to enrol me in the study, I have a right to refuse or to stop my 
involvement anytime during the study. 
……………………………………………………………………………………………… 
Child Name                                              Signature/thumbprint                                      Date 
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Appendix 5: Data collection form 
 
The clinical examination  
 
1. Age 
2. Gender 
3. Race 
4. Date of diagnosis 
5. Mode of HIV transmission 
6. CD4 count:  at diagnosis...................... at present...........................  
CD8 count:  at diagnosis.......................at present...........................  
Viral load:    at diagnosis......................at present...........................  
Facial examination 
Swelling present       Yes.............................          No......................................  
Glands involved:       Parotid........................ Submandibular................... 
Unilateral...................          Bilateral............................. 
Size:         Left............................          Right..................................  
Texture of swelling:   Hard...........................         Soft....................................  
Associated symptoms:  Pain                      Y/N 
                                     Dry mouth            Y/N 
                                     Caries                   Y/N 
Other symptoms          Oral candidiasis    Y/N 
                                     Gingivitis/bleeding gums Y/N 
                                     Mouth ulcers        Y/N 
 Associated cervical lymphadenopathy: Yes/No 
Other medical pathology 
Antiretroviral therapy history 
Effect of ARV: On parotid swellings 
                    On CD4 count 
   On viral load
Appendix 6 Raw data Group 1  
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Group 2 children data 
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1 1 male African 2007 vertical 889 14.6 1261 28.7 2 100 000  caries no 
d4T, 3TC, 
EFV 1  
2 2 female African 
2008 
Nov vertical 983 18.8      no 
not on 
treatment   
3 2 male African 
2008 
May unknown 690       no d4T,3TC, EFV 11 coughing 
4 3 female African 2006 vertical 759 9.3   160 000   no 
d4T, 3TC, 
EFV 5 TB 
5 3 female African 2007 Oct vertical 429 10.1   2 400 000   yes d4T,3TC, EFV 36 
TB, Varicella 
zoster 
6 3 male African 
2008 
July unknown 262 10.9     caries no 
d4T, 3TC, 
Kaletra 3  
7 4 female African 2006 Dec vertical 861  1646  33 000 <25 caries no d4T,3TC, EFV 24 TB 
8 4 male African 
2006 
Nov vertical 399  57  55 000 6100  no d4T,3TC, EFV 24  
9 4 male African 
2005 
May vertical 1198 22.1 558 22.2 150 000 
lower than 
detectable 
oral candidiasis, 
erythematous no d4T,3TC, EFV 36  
10 5 female African 2003 vertical 197 7.62   5 200  oral candidiasis no 
not on 
treatment 13 TB 
11 5 female African 2003 vertical 198    5 300  1900 oral candidiasis no d4T,3TC, EFV 14 TB 
12 5 male African 2008 Jun vertical 224    58 000  
caries, oral candidiasis, 
oral ulcers, gingivitis yes d4T, 3TC,EFV 3 
varicella 
zoster, wasting 
syndrome 
13 6 female African 2005 Jun vertical 306 12 952 34.9 350 000 0  no d4T,3TC, EFV 36 TB 
14 6 male African  vertical 700 8.11 929  27 000 
lower than 
detectable 
caries, oral candidiasis, 
gingivitis no 
d4T, 3TC, 
EFV 8 TB 
15 7 female African 2007 vertical 16 1.4 16 13.5 26 000 37 caries no d4T, 3TC,EFV 17 TB 
16 8 female African 2005 Jul vertical 110 5.66 631 22.7 160 000 <25  caries, oral candidiasis no d4T,3TC, EFV 36 TB 
17 8 female African 2007 Oct vertical 650 25 316 16.1   caries yes 
not on 
treatment  TB 
18 9 female African 
2005 
Aug vertical 55 4.7 871 39.5 140 000 
lower than 
detectable caries no 
d4T, 3TC, 
EFV 48 TB 
19 10 male African 2005 vertical 391 8.36 649 35.1 98 000 
lower than 
detectable caries no d4T,3TC, EFV 36 
TB, 
Lipodystrophy 
20 10 male African 2005 vertical 489 17.8     gingivitis, mouth ulcers no 
not on 
treatment   
21 11 female African 
2009 
mar vertical 381 14.7   720 000  
caries, oral candidiasis, 
erythematous no 
not on 
treatment  
facial and 
head fungal 
infection 
22 11 male African 
2008 
Aug vertical 164 19.3   2 500  oral candidiasis yes d4T,3TC, EFV 3 
varicella 
zoster 
23 11 male African 2008 Oct vertical 43 3.64     
oral candidiasis, mouth 
ulcers no d4T,3TC, EFV 1  
24 12.7 male African 2006 Dec vertical 12 0.87 282 13.7 50 000 
lower than 
detectable caries yes 
d4T, 3TC, 
EFV 18 TB 
 
 
 
 
 
